Engaging healthcare teams to increase access to medications for opioid use disorder

被引:1
|
作者
Oberman, Rebecca S. [1 ]
Huynh, Alexis K. [1 ]
Cummings, Kelsey [1 ]
Resnick, Adam [1 ]
Taylor, Stephanie L. [1 ,2 ,3 ]
Bergman, Alicia A. [1 ]
Chang, Evelyn T. [1 ,4 ]
机构
[1] VHA Ctr Study Healthcare Innovat Implementat & Pol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA
[4] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gen Internal Med, Los Angeles, CA USA
关键词
buprenorphine; implementation science; methadone; naltrexone; opioid use disorder; quality improvement; QUALITY IMPROVEMENT; BUPRENORPHINE TREATMENT; UNITED-STATES; OVERDOSE; DEPRESSION; GUIDELINE; NALOXONE; OUTCOMES; LESSONS;
D O I
10.1111/1475-6773.14371
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
ObjectiveTo assess the effectiveness of evidence-based quality improvement (EBQI) as an implementation strategy to expand the use of medications for opioid use disorder (MOUD) within nonspecialty settings.Data Sources and Study SettingWe studied eight facilities in one Veteran Health Administration (VHA) region from October 2015 to September 2022 using administrative data.Study DesignInitially a pilot, we sequentially engaged seven of eight facilities from April 2018 to September 2022 using EBQI, consisting of multilevel stakeholder engagement, technical support, practice facilitation, and data feedback. We established facility-level interdisciplinary quality improvement (QI) teams and a regional-level cross-facility collaborative. We used a nonrandomized stepped wedge design with repeated cross sections to accommodate the phased implementation. Using aggregate facility-level data from October 2015 to September 2022, we analyzed changes in patients receiving MOUD using hierarchical multiple logistic regression.Data Collection/Extraction MethodsEligible patients had an opioid use disorder (OUD) diagnosis from an outpatient or inpatient visit in the previous year. Receiving MOUD was defined as having been prescribed an opioid agonist or antagonist treatment or a visit to an opioid substitution clinic.Principal FindingsThe probability of patients with OUD receiving MOUD improved significantly over time for all eight facilities (average marginal effect [AME]: 0.0057, 95% CI: 0.0044, 0.0070) due to ongoing VHA initiatives, with the probability of receiving MOUD increasing by 0.577 percentage points, on average, each quarter, totaling 16 percentage points during the evaluation period. The seven facilities engaging in EBQI experienced, on average, an additional 5.25 percentage point increase in the probability of receiving MOUD (AME: 0.0525, 95%CI: 0.0280, 0.0769). EBQI duration was not associated with changes.ConclusionsEBQI was effective for expanding access to MOUD in nonspecialty settings, resulting in increases in patients receiving MOUD exceeding those associated with temporal trends. Additional research is needed due to recent MOUD expansion legislation.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] ENGAGING HEALTH CARE TEAMS TO INCREASE ACCESS TO MEDICATIONS FOR OPIOID USE DISORDER
    Oberman, Rebecca
    Huynh, Alexis
    Resnick, Adam
    Cummings, Kelsey
    Taylor, Stephanie L.
    Bergman, Alicia
    Chang, Evelyn T.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 : S309 - S310
  • [2] Rapid Access to Medications for Opioid Use Disorder
    Kleinman, Robert A.
    Morris, Nathaniel P.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (11) : 3557 - 3558
  • [3] Rapid Access to Medications for Opioid Use Disorder
    Robert A. Kleinman
    Nathaniel P. Morris
    Journal of General Internal Medicine, 2021, 36 : 3557 - 3558
  • [4] Trends in Access to Medications for Opioid Use Disorder
    Gupta, Sumedha
    James, Aditya
    Miles, Jennifer
    Samples, Hillary
    Crystal, Stephen
    Simon, Kosali
    JAMA HEALTH FORUM, 2025, 6 (04):
  • [5] State Policies Could Impede New Efforts to Increase Access to Medications for Opioid Use Disorder
    Barsky, Benjamin A.
    Mehrotra, Ateev
    Huskamp, Haiden A.
    JAMA HEALTH FORUM, 2023, 4 (03):
  • [6] Probation clients' barriers to access and use of opioid use disorder medications
    Reichert, Jessica
    Gleicher, Lily
    HEALTH & JUSTICE, 2019, 7 (01)
  • [7] Probation clients’ barriers to access and use of opioid use disorder medications
    Jessica Reichert
    Lily Gleicher
    Health & Justice, 7
  • [8] The opioid epidemic in rural communities: Can telehealth increase access to medications for opioid use disorder and offset barriers to care?
    Meyers, Kathleen
    Herman, Shannon
    Schuler, Heather
    Mun, Carolyn
    Bresani, Elena
    Payne, Richard Koban
    DRUG AND ALCOHOL DEPENDENCE, 2025, 271
  • [9] A Step Toward Equity: Evidence-Based Policy for Access to Medications for Healthcare Workers With Opioid Use Disorder
    Salzman, Matthew
    Bryan, Rebecca H.
    Sharfstein, Joshua M.
    JOURNAL OF NURSING REGULATION, 2023, 14 (03) : 14 - 19
  • [10] Innovative Payment to Scale Up Access to Medications for Opioid Use Disorder
    Polsky, Daniel
    Sen, Aditi P.
    Arsenault, Samantha
    AMERICAN JOURNAL OF MANAGED CARE, 2020, 26 (07): : 286 - 287